Stockscreener 앱 받기
1.70
1.16%
-0.02
전일 마감가:
$1.72
열려 있는:
$1.73
하루 거래량:
1.55M
Relative Volume:
0.30
시가총액:
$144.79M
수익:
-
순이익/손실:
$-59.69M
주가수익비율:
-1.223
EPS:
-1.39
순현금흐름:
$-46.54M
1주 성능:
-3.41%
1개월 성능:
-11.92%
6개월 성능:
-2.30%
1년 성능:
-25.76%
1일 변동 폭
$1.68
$1.74
1주일 범위
$1.68
$1.89
52주 변동 폭
$0.6254
$3.06
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
명칭
Milestone Pharmaceuticals Inc
전화
(514) 336-0444
주소
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Compare MIST vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
1.70 | 146.49M | 0 | -59.69M | -46.54M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-15 | 업그레이드 | TD Cowen | Hold → Buy |
| 2025-09-11 | 개시 | Wells Fargo | Overweight |
| 2025-06-05 | 재개 | H.C. Wainwright | Buy |
| 2024-08-22 | 개시 | Rodman & Renshaw | Buy |
| 2023-06-20 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-04-22 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-03-05 | 개시 | H.C. Wainwright | Buy |
| 2020-07-29 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-07-24 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-03-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-03-24 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-03-24 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2019-06-04 | 개시 | Oppenheimer | Outperform |
| 2019-06-03 | 개시 | Cowen | Outperform |
| 2019-06-03 | 개시 | Jefferies | Buy |
| 2019-06-03 | 개시 | Piper Jaffray | Overweight |
모두보기
Milestone Pharmaceuticals Inc 주식(MIST)의 최신 뉴스
Why analysts upgrade Milestone Pharmaceuticals Inc. stock2025 Price Targets & Real-Time Stock Price Movement Reports - mfd.ru
What is the long term forecast for Milestone Pharmaceuticals Inc. stock2025 Biggest Moves & Daily Profit Maximizing Tips - mfd.ru
Why Milestone Pharmaceuticals Inc. stock is a value investor pickTrade Analysis Summary & Risk Adjusted Buy/Sell Alerts - mfd.ru
Milestone Pharmaceuticals appoints David Sandoval as general counsel By Investing.com - Investing.com South Africa
Milestone Pharmaceuticals appoints David Sandoval as general counsel - Investing.com
Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer - The Manila Times
Milestone Pharmaceuticals (MIST) Awards New Equity Options - GuruFocus
Milestone Pharmaceuticals reports inducement grants under Nasdaq listing rule - TipRanks
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Published on: 2026-02-03 14:31:32 - baoquankhu1.vn
Market Review: Is Milestone Pharmaceuticals Inc a momentum stockJuly 2025 Recap & Daily Oversold Bounce Ideas - baoquankhu1.vn
Milestone Pharmaceuticals (NASDAQ:MIST) Insider David Bharucha Sells 12,245 Shares - MarketBeat
Milestone Pharmaceuticals (NASDAQ:MIST) Insider Lorenz Muller Sells 11,180 Shares - MarketBeat
Insider Selling: Milestone Pharmaceuticals (NASDAQ:MIST) Insider Sells $124,273.12 in Stock - MarketBeat
Milestone Pharmaceuticals (NASDAQ:MIST) CEO Sells $66,629.39 in Stock - MarketBeat
Jeffrey Edward Nelson Sells 58,007 Shares of Milestone Pharmaceuticals (NASDAQ:MIST) Stock - MarketBeat
Insider Selling: Milestone Pharmaceuticals (NASDAQ:MIST) Insider Sells 58,007 Shares of Stock - MarketBeat
Milestone Pharmaceuticals (NASDAQ:MIST) Rating Increased to Strong-Buy at Zacks Research - MarketBeat
All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy - Yahoo Finance
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) - Finviz
Milestone Pharmaceuticals announces U.S. availability of cardamyst - Yahoo Finance
Milestone’s PSVT treatment CARDAMYST now available in US pharmacies By Investing.com - Investing.com Canada
Milestone Launches CARDAMYST Nasal Spray in U.S. Pharmacies - TipRanks
Milestone Pharmaceuticals (MIST) Launches Cardamyst Nasal Spray in U.S. Market - GuruFocus
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) - Taiwan News
Bull Run: Should I set a stop loss on Milestone Pharmaceuticals IncJuly 2025 Action & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Aug Fed Impact: Will Cohen Circle Acquisition Corp I outperform during market ralliesJuly 2025 Retail & Free Verified High Yield Trade Plans - baoquankhu1.vn
Insider Trends: Is Milestone Pharmaceuticals Inc undervalued by DCF analysisJuly 2025 Reactions & Real-Time Chart Breakout Alerts - baoquankhu1.vn
Hedge Fund Bets: What is the long term forecast for Milestone Pharmaceuticals Inc stockM&A Rumor & Growth Focused Investment Plans - baoquankhu1.vn
Earnings Miss: Is Milestone Pharmaceuticals Incs ROIC above industry averageJuly 2025 Closing Moves & Growth Focused Stock Reports - baoquankhu1.vn
Aug Mood: Should I invest in Milestone Pharmaceuticals Inc before earningsCPI Data & Daily Profit Focused Screening - baoquankhu1.vn
US Stocks Recap: Is Milestone Pharmaceuticals Inc vulnerable to short sellers2025 Historical Comparison & Stock Timing and Entry Methods - baoquankhu1.vn
Swing Trade: How does Milestone Pharmaceuticals Inc compare to its peersWeekly Trend Summary & Long-Term Growth Plans - baoquankhu1.vn
Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense (MIST) - Seeking Alpha
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
ETF Watch: Will Milestone Pharmaceuticals Inc. stock gain from lower inflation2025 Institutional Moves & Technical Pattern Recognition Alerts - Bộ Nội Vụ
Milestone Pharmaceuticals Secures $75M Non-Dilutive Royalty Financing - TipRanks
Milestone Pharmaceuticals Completes Royalty Interest Sale - TradingView
Will Milestone Pharmaceuticals Inc. stock gain from lower inflationWeekly Trend Recap & Detailed Earnings Play Strategies - Улправда
Milestone Pharmaceuticals (NASDAQ:MIST) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Insider Sell: Joseph Oliveto Sells 43,500 Shares of Milestone Ph - GuruFocus
Joseph Oliveto Sells 43,000 Shares of Milestone Pharmaceuticals (NASDAQ:MIST) Stock - MarketBeat
Trend Report: Will Milestone Pharmaceuticals Inc stock gain from government policies2025 Volume Leaders & Safe Capital Growth Tips - Bộ Nội Vụ
How Milestone Pharmaceuticals Inc. stock benefits from global expansion2025 Growth vs Value & Real-Time Market Sentiment Alerts - Улправда
How supply chain issues affect Milestone Pharmaceuticals Inc. stockJuly 2025 Earnings & Detailed Earnings Play Alerts - Улправда
Will Milestone Pharmaceuticals Inc. stock gain from government policies2025 Sector Review & Risk Managed Investment Strategies - Улправда
Can Milestone Pharmaceuticals Inc. stock continue upward trendJuly 2025 Sentiment & Capital Efficient Trading Techniques - Улправда
Is Milestone Pharmaceuticals Inc. stock a buy in volatile markets2025 Growth vs Value & Short-Term Trading Alerts - Улправда
Milestone announces acceptance of MAA by EMA for etripamil nasal spray - Yahoo Finance
MIST: HC Wainwright & Co. Reiterates Buy Rating with $8 Price Ta - GuruFocus
Milestone Pharmaceuticals (NASDAQ:MIST) Earns Buy Rating from HC Wainwright - MarketBeat
Milestone Pharmaceuticals Inc (MIST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Milestone Pharmaceuticals Inc 주식 (MIST) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Bharucha David | Chief Medical Officer |
Jan 26 '26 |
Sale |
1.93 |
12,245 |
23,633 |
113,181 |
| Nelson Jeffrey Edward | Chief Operating Officer |
Dec 15 '25 |
Sale |
2.32 |
58,007 |
134,576 |
41,993 |
| Nelson Jeffrey Edward | Chief Operating Officer |
Jan 26 '26 |
Sale |
1.93 |
12,245 |
23,633 |
49,848 |
| Muller Lorenz | Chief Commercial Officer |
Dec 15 '25 |
Sale |
2.32 |
53,566 |
124,273 |
196,486 |
| Muller Lorenz | Chief Commercial Officer |
Jan 26 '26 |
Sale |
1.93 |
11,180 |
21,577 |
205,406 |
| Hasija Amit | CFO & EVP of Corp. Development |
Dec 15 '25 |
Sale |
2.32 |
58,007 |
134,576 |
91,993 |
| Hasija Amit | CFO & EVP of Corp. Development |
Jan 26 '26 |
Sale |
1.93 |
12,245 |
23,633 |
99,848 |
| Oliveto Joseph | President and CEO |
Dec 15 '25 |
Sale |
2.32 |
133,054 |
308,685 |
450,667 |
| Oliveto Joseph | President and CEO |
Jan 26 '26 |
Sale |
1.93 |
34,523 |
66,629 |
482,744 |
| Oliveto Joseph | President and CEO |
Jan 08 '26 |
Sale |
2.25 |
43,000 |
96,750 |
303,721 |
1.12%
0.87%
자본화:
|
볼륨(24시간):